Histamine-Releasing Properties of T-3762, a Novel Fluoroquinolone Antimicrobial Agent in Intravenous Use. I. Effects of Doses and Infusion Rate on Blood Pressure, Heart Rate and Plasma Histamine Concentration.

1998 ◽  
Vol 21 (5) ◽  
pp. 456-460 ◽  
Author(s):  
Kunikazu FURUHATA ◽  
Hiroyoshi HAYAKAWA ◽  
Keiji SOUMI ◽  
Hirotoshi ARAI ◽  
Yasuo WATANABE ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Antimicrobial Agent ◽  
Infusion Rate ◽  
Plasma Histamine ◽  
Histamine Concentration ◽  
Plasma Histamine Concentration

Elevation of the plasma histamine concentration in the coronary circulation in patients with variant angina

1996 ◽  
Vol 77 (12) ◽  
pp. 1121-1126 ◽  
Author(s):  
Yasuhiko Sakata ◽  
Kazuo Komamura ◽  
Atsushi Hirayama ◽  
Shinsuke Nanto ◽  
Masafumi Kitakaze ◽  
...  
Keyword(s):  
Coronary Circulation ◽  
Variant Angina ◽  
Plasma Histamine ◽  
Histamine Concentration ◽  
Plasma Histamine Concentration

Base-line and postthermal injury plasma histamine in rats

1986 ◽  
Vol 60 (5) ◽  
pp. 1782-1788 ◽  
Author(s):  
R. W. Yurt ◽  
B. A. Pruitt
Keyword(s):  
Human Plasma ◽  
Thermal Injury ◽  
Sampling Technique ◽  
Rat Plasma ◽  
Base Line ◽  
Plasma Histamine ◽  
Histamine Concentration ◽  
Partial Thickness Burn ◽  
Plasma Histamine Concentration ◽  
Normal Rat

Although plasma histamine concentration has been reported to increase after thermal injury in the rat to as much as 100-fold over normal human plasma levels, the pathophysiological significance and relevance to human disease is questionable. Lack of confidence in the rat as a model of histamine-mediated disease is based on reports that normal rat base-line plasma histamine concentration exceeds that of human plasma by 20- to 70-fold. The present study confirms that high concentrations of histamine (20–68.9 ng/ml) are found in rat plasma obtained in an uncontrolled manner; but concentrations are lower (1.17 +/- 0.49 ng/ml) or undetectable in a sensitive radioenzymatic assay when sampling technique and plasma isolation are controlled. The primary cause for falsely elevated values for plasma histamine concentration appeared to be due to manipulation of the rat. Plasma histamine concentration increased within 1 min after thermal injury and the increase was proportional to extent of surface area injured. In contrast to the finding of a single time-related peak of plasma histamine concentration after partial-thickness burn, a biphasic elevation was found after full-thickness injury. Thus the data indicate that normal rat plasma histamine concentration is similar to that of the human and below the reported threshold for modulation of a variety of immune responses. Furthermore, the data support a role for histamine and other mast-cell mediators in the local and systemic responses to injury.

The Cardiovascular Effects and Histamine-releasing Properties of 51W89 in Patients Receiving Nitrous Oxide/Opioid/Barbiturate Anesthesia 

1995 ◽  
Vol 82 (5) ◽  
pp. 1131-1138 ◽  
Author(s):  
Cynthia A. Lien ◽  
Matthew R. Belmont ◽  
Amy Abalos ◽  
Larissa Eppich ◽  
Steve Quessy ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Nitrous Oxide ◽  
Surgical Procedures ◽  
Muscle Relaxant ◽  
Venous Blood ◽  
Cardiovascular Effects ◽  
Plasma Histamine ◽  
Elective Surgical Procedures ◽  
Rapid Injection

Background Atracurium consists of a mixture of ten stereoisomers. One of these isomers, 51W89, is a potent intermediate-acting nondepolarizing neuromuscular blocking agent. Its ED95 is 0.05 mg.kg-1 in patients receiving nitrous oxide/opioid anesthesia. In preclinical trials, 51W89 did not show evidence of histamine release in cats at doses up to 80 times the human ED95. This study was undertaken to determine the cardiovascular effects and histamine-releasing properties of 51W89 in patients undergoing elective surgical procedures. Methods Sixty patients, ASA physical status 1 or 2, anesthetized with nitrous oxide/fentanyl/thiopental were studied. Patients received either 2 times the ED95 of atracurium or 51W89 or 4 or 8 times the ED95 of 51W89 as a rapid intravenous bolus under stable anesthesia, before surgical stimulation. Blood pressure and heart rate were measured by oscillometry and the electrocardiogram in patients receiving 2 times the ED95 of 51W89 or atracurium and by an intraarterial catheter and a tachograph triggered by the arterial pulse waveform in patients receiving 4 or 8 times the ED95 of 51W89. Maximal blood pressure and heart rate changes during the 5 min after administration of the muscle relaxant were recorded. Venous blood samples were obtained before the administration of relaxant and at 2 and 5 min after the administration of relaxant for determination of plasma histamine concentrations by radioenzymatic assay. Results Maximal blood pressure and heart rate changes in all groups of patients receiving 51W89 were small and similar to those observed in patients receiving 2 times the ED95 of atracurium. The mean maximum percent changes (+/- SE) in heart rate and mean arterial pressure were -0.6 +/- 1.5 and 0.4 +/- 2.5, respectively, in the group receiving 2 times the ED95 atracurium; -1.3 +/- 3.3 and 2.3 +/- 4.4, respectively, in the group receiving 2 times the ED95 51W89; -2.6 +/- 1.0 and 2.6 +/- 1.5, respectively, in the group receiving 4 times the ED95 51W89; and -2.4 +/- 1.5 and -1.0 +/- 1.3, respectively, in the group receiving 8 times the ED95 51W89. No patient developed a decrease in blood pressure > or = 20% or an increase in heart rate > or = 20% that was attributable to muscle relaxant administration. There was no dose-related change in plasma histamine concentration associated with the administration of 51W89. One patient in the study developed transient facial flushing after the administration of atracurium. Conclusions 51W89 is a benzylisoquinolinium-type, nondepolarizing muscle relaxant that does not affect plasma histamine concentrations. No cutaneous flushing or clinically important cardiovascular effects were noted after rapid injection of doses up to and including 8 times its ED95 (0.4 mg.kg-1) in healthy patients undergoing elective surgical procedures.

Plasma Histamine and Catecholamines in Stable Asthmatic Subjects

1982 ◽  
Vol 62 (6) ◽  
pp. 661-665 ◽  
Author(s):  
P. J. Barnes ◽  
P. W. Ind ◽  
M. J. Brown
Keyword(s):  
Chronic Obstructive ◽  
Plasma Catecholamine ◽  
Plasma Histamine ◽  
Histamine Concentration ◽  
Plasma Histamine Concentration ◽  
Obstructive Airways Disease ◽  
Plasma Catecholamine Concentrations ◽  
Chronic Obstructive Airways Disease ◽  
Normal Controls ◽  
Venous Plasma

1. Venous plasma histamine and catecholamines were measured in stable asthmatic subjects by a recently developed specific and sensitive radioenzymatic assay. 2. Plasma histamine concentrations were significantly elevated in both extrinsic and intrinsic asthmatic subjects, compared with both normal controls and patients with chronic obstructive airways disease. There was no correlation between histamine concentration and severity of airways obstruction, however. 3. Elevated plasma histamine concentrations at rest-5-indicate increased release of mediators from ‘leaky’ mast cells in asthma. 4. Plasma catecholamine concentrations in asthmatic subjects did not differ from normal and there was no correlation with severity of broncho- constriction or with plasma histamine concentration.

Changes in plasma histamine concentration in the streptozotocin-diabetic rat

1985 ◽  
Vol 43 (1) ◽  
pp. 90-96 ◽  
Author(s):  
Theodore M. Hollis ◽  
John A. Kern ◽  
Ned A. Enea ◽  
Andrew J. Cosgarea
Keyword(s):  
Diabetic Rat ◽  
Plasma Histamine ◽  
Histamine Concentration ◽  
Plasma Histamine Concentration ◽  
Streptozotocin Diabetic Rat

Histamine, Basophils and Eosinophils in Severe Asthma

1979 ◽  
Vol 57 (1) ◽  
pp. 39-45 ◽  
Author(s):  
T. J. Charles ◽  
S. J. Williams ◽  
A. Seaton ◽  
Christine Bruce ◽  
W. H. Taylor
Keyword(s):  
Severe Asthma ◽  
Whole Blood ◽  
Normal Subjects ◽  
Control Group ◽  
Plasma Histamine ◽  
Histamine Concentration ◽  
Basophil Cell ◽  
Plasma Histamine Concentration ◽  
Blood Histamine ◽  
Venous Plasma

1. Arterial and venous whole blood and plasma histamine concentrations and eosinophil and basophil counts were determined in five patients with acute severe asthma who had not previously received steroid therapy, in five who had been maintained on steroid therapy and in a control group of nine patients with acute non-respiratory illnesses. 2. No significant arteriovenous differences were observed for any of these measurements in any of the groups of patients. Significant net loss of arterial histamine does not therefore occur peripherally in acute asthma. 3. When compared with the values for the controls, statistically significant increases were observed, in the group not receiving steroids, for arterial and venous whole blood histamine concentrations, eosinophil counts and basophil counts, and, in those receiving steroids, for the venous basophil counts. 4. When compared with the venous plasma histamine concentration of normal subjects, that of the asthmatic subjects not receiving steroids was significantly raised. 5. The venous plasma histamine concentration of the control group was also significantly higher than that of normal subjects, but less so than in the asthmatic subjects, suggesting that acute illness per se produces an increased plasma histamine concentration. 6. Both groups of asthmatic patients were treated similarly with hydrocortisone and bronchodilators. There was a striking fall in whole blood histamine concentration and in eosinophil and basophil counts, but plasma histamine fell more slowly, especially in those who had not previously received steroids. 7. The mean histamine content of the basophil cell is 0·01 pmol and significant differences in this value did not occur within the various groups or as a result of treatment. The approximate number of molecules of histamine per basophil cell is 6·0 × 109.

Sign in / Sign up

Export Citation Format

Share Document